House Majority Leader Steve Scalise has a ‘very treatable’ blood cancer

House Majority Leader Steve Scalise has a ‘very treatable’ blood cancer


U.S. House Majority Leader Rep. Steve Scalise (R-La.) listens during a press conference following a House Republican Conference meeting at the U.S. Capitol Building in Washington, D.C., July 18, 2023.

Anna Moneymaker | Getty Images

House Majority Leader Steve Scalise said Tuesday that he has been diagnosed with multiple myeloma, which he called “a very treatable blood cancer.”

The Louisiana Republican underwent tests after “not feeling like myself this past week,” he said in a statement. “I have now begun treatment, which will continue for the next several months.”

Scalise, 57, said he intends to continue working as he receives treatment and will return to Washington, D.C., but did not say precisely when.

Congress is slated to return to the U.S. Capitol after Labor Day for a busy month.

This isn’t the first time Scalise has dealt with a major health scare.

In 2017, he was one of six people injured in a mass shooting in Alexandria, Virginia, during a team practice for the annual Congressional Baseball Game.

Scalise was shot in the hip and the bullet ruptured several organs. He underwent months of surgeries and blood transfusions on the way to recovery.



Source

OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More
Thanks for your support, here’s how to connect with us
Health

Thanks for your support, here’s how to connect with us

When Becky Quick announced the CNBC Cures initiative, our effort to raise awareness for rare diseases and improve the lives of the 30 million people living with them, we knew the response would be big. We didn’t know it would be this big. The response has been amazing, overwhelming and humbling. Thank you for your interest — […]

Read More
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More